drug
Renvela
Marketedupdated 3mo agoby Sanofi-Aventis US LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4all catalysts(1)
Trials studying Renvela
- phase3AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia
- phase3FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney Disease
- phase2Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia
- phase4Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders
- phase3Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis
- phase2A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients
- phase3A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 6, 2030
~4.3 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- Dec 6, 2030formulationUS 90955094.3y
- Dec 6, 2030formulationUS 90955094.3y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 25m ago
Found something off?
comments(0)
5-min edit window · permanent after that